Lazertinib (Lazcluze) 80mg | Janssen China Originator | GLT

Generic Information: Lazcluze 利珂 (China)

This listing is the China-market presentation of Lazcluze, marketed locally under the Chinese trade name 利珂 (Li Ke). Approved by China's National Medical Products Administration in 2025, the product is produced and packaged by Xi'an Janssen, the Chinese arm of Johnson & Johnson, and reaches patients as bottles of ninety 80 mg tablets — a one-to-one match with the American originator molecule developed from Yuhan's Korean research programme.

What Is Lazertinib (Lazcluze) Used For?

Lazertinib treats advanced non-small cell lung cancer driven by sensitising EGFR mutations, principally exon 19 deletions and the L858R point mutation, and the T790M resistance mutation that emerges after earlier-generation EGFR therapy. In China the medicine is used within combination protocols that pair daily oral lazertinib with amivantamab (Rybrevant) or with chemotherapy, mirroring the first-line regimen validated in the global MARIPOSA programme.

How Does Lazertinib Work?

Tumour cells with EGFR mutations depend on a continuously switched-on growth receptor. Lazertinib is a selective, irreversible kinase inhibitor that locks onto the mutant EGFR protein and blocks its signalling permanently, while showing minimal interference with healthy wild-type EGFR. The drug distributes well into brain tissue, which matters because the brain is a frequent site of spread in EGFR-driven lung cancer. Blocking the receptor restores immune visibility of the tumour and slows proliferation at its molecular source.

Indications

Suitable patients are adults with locally advanced or metastatic NSCLC confirmed by tissue or blood genetic testing to carry EGFR exon 19 deletion or exon 21 L858R mutations. Treatment decisions — including combination with amivantamab and sequencing after other EGFR inhibitors — are made by respiratory oncologists, and baseline assessments typically include staging imaging and cardiac function checks before the first dose.

Dosage

One 240 mg dose is taken once a day by mouth, at any time relative to meals, swallowed whole without crushing or splitting; the 240 mg daily amount corresponds to three 80 mg tablets such as the ninety-tablet bottle supplied here. Therapy runs in continuous daily cycles until progression or intolerance. Doses are not reduced for mild side effects without specialist guidance, and amivantamab infusions follow their own institutional schedule alongside the tablets.

Side Effects

Treatment most often brings skin changes — rash, dryness and nail-fold inflammation — together with diarrhoea, mouth ulcers, tiredness, joint or muscle aches and reduced appetite. Laboratory changes such as lowered thyroid hormone and low magnesium are monitored with routine blood tests. The combination regimen additionally carries risks of infusion reactions, blood clots in veins and drug-induced lung inflammation, all of which are managed best when reported early to the treating team.

Storage

As an oral tablet presentation, 利珂 bottles are kept at room temperature in a dry place away from direct sunlight, with no cold chain required. Original sealed bottles are shipped by ambient courier from GLT's Hong Kong-licensed facility, each accompanied by full sourcing documentation.

Why Choose Lazcluze 利珂 Through GLT?

The China presentation offers the genuine Janssen-originator molecule at the locally regulated Chinese pack size of ninety tablets, sourced through GLT's Hong Kong base for overseas buyers who need NMPA-approved packaging with verifiable approval documentation. Chinese-origin stock also shortens delivery routes across Asia while remaining fully traceable batch by batch.

How to Order

To order the China-market Lazcluze 利珂 (lazertinib), contact GLT on WhatsApp at +86 15234153837 or by email at [email protected]. We confirm availability, pack options and shipping to your country before payment, and dispatch from a Hong Kong-licensed facility.

FAQ

What is 利珂? 利珂 (Li Ke) is the Chinese trade name of Lazcluze, the Janssen originator brand of lazertinib approved by the NMPA and manufactured by Xi'an Janssen.

How many tablets are in one bottle? The Chinese presentation contains ninety 80 mg tablets per bottle — a ten-day supply at the standard 240 mg daily dose.

Does Chinese Lazcluze work the same as the US version? Yes — same molecule, same 80 mg tablet strength; only packaging, language and local regulatory presentation differ.